ABC | Volume 115, Nº1, July 2020

Original Article Macedo et al. Resistant hypertension in afrodescendants Arq Bras Cardiol. 2020; 115(1):31-39 that of those who historically attend the health unit where the study was conducted. The stratification of individuals as resistant or refractory took into account the control of BP and the number of drugs prescribed, disregarding whether or not they were using chlortalidone and spironolactone, which, according to some authors, may have overestimated the prevalence of RfH. Conclusions Individuals with RH followed up at this referral clinic for the treatment of severe cases of SAH were mostly of African descent, with a high prevalence of risk factors for cardiovascular diseases and, consequently, high cardiovascular risk according to the FRS. We found a high proportion of individuals with the most severe form of phenotypic resistance to the treatment of hypertension, defined as RfH, who had a higher frequency of dyslipidemia and a history of stroke compatible with a possibly higher frequency of damage to target organs. Further more comprehensive studies should be carried out to improve knowledge about the characteristics of this high-risk population, contributing to the definition of appropriate prevention and treatment strategies. Author contributions Conception and design of the research: Macedo C, Aras Junior R; Acquisition of data: Macedo C, Macedo IS; Analysis and interpretation of the data and Critical revision of the manuscript for intellectual content: Macedo C, Aras Junior R, Macedo IS; Statistical analysis and writing of the manuscript: Macedo C. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This article is part of the thesis of Doctoral submitted by Cistiano Macedo, from Faculdade de Medicina da Universidade Federal da Bahia. Ethics approval and consent to participate This study was approved by the Ethics Committee of the Hospital Ana Nery under the protocol number 138.371. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 1. Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046–58. 2. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ ASPC/NMA/PCNAGuideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/AmericanHeart Association Task Force on Clinical Pr. Hypertension. 2018 Jun;71(6):e13–115. 3. MalachiasM,SouzaW,PlavnikF,RodriguesC,BrandãoA,NevesM.VIIDiretriz BrasileiraDeHipertensãoArterial.ArqBrasCardiol.2016;107(3Supl.3):1–83. 4. ManciaG,FagardR,NarkiewiczK,Redon J,ZanchettiA,BöhmM,etal.2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–219. 5. Departamento de Hipertensão Arterial da Sociedade Brasileira de Cardiologia. I Posicionamento Brasileiro Sobre Hipertensão Arterial Resistente. Arq Bras Cardiol. 2012;99(1):576–85. 6. TanjaDudenbostel*,MohammedSiddiqui,NitinGharpureADAC.Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;21(2):129–39. 7. CalhounDA,BoothJN,OparilS,IrvinMR,ShimboD,LacklandDT,etal.Refractory Hypertension:DeterminationofPrevalence,RiskFactors,andComorbiditiesina Large,Population-BasedCohort.Hypertension.2014;63(3):451–8. 8. Acelajado MC, Pisoni R, Dudenbostel T, Dell’Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: Definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14(1):7–12. 9. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement FromtheAmericanHeartAssociationProfessionalEducationCommitteeofthe CouncilforHighBloodPressureResearch.Circulation.2008;117(25):e510–26. 10. Sarganas G, Neuhauser HK. Untreated, Uncontrolled, and Apparent Resistant Hypertension: Results of the German Health Examination Survey 2008-2011. J Clin Hypertens. 2016;18(11):1146–54. 11. Judd E, Calhoun DA. Apparent and true resistant hypertension: Definition, prevalence and outcomes. J HumHypertens. 2014;28(8):463–8. 12. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: What the cardiologist needs to know. Eur Heart J. 2015;36(40):2686–695c. 13. Dudenbostel T. Resistant hypertension - Complex mix of secondary causes and comorbidities. J HumHypertens. 2014;28(1):1–2. 14. DudenbostelT,AcelajadoMC,PisoniR,LiP,OparilS,CalhounDA.Refractory hypertension: Evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66(1):126–33. 15. SiddiquiM,CalhounDA.Refractoryversusresistanthypertension.CurrOpin Nephrol Hypertens. 2017;26(1):14–9. 16. Modolo R, De Faria AP, Sabbatini AR, Barbaro NR, Ritter AMV, Moreno H. Refractory and resistant hypertension: Characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9(5):397–402. References 37